Equities
Health CarePharmaceuticals and Biotechnology
  • Price (HKD)26.70
  • Today's Change1.40 / 5.53%
  • Shares traded2.40m
  • 1 Year change-23.17%
  • Beta0.8353
Data delayed at least 15 minutes, as of May 28 2024 09:08 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

RemeGen Co Ltd is a China-based company mainly engaged in the research, development and manufacture of innovative biopharmaceuticals. The Company is mainly engaged in the discovery, development and commercialization of therapeutic antibody drugs such as antibody drug conjugates (ADCs), antibody fusion proteins, monoclonal antibodies and bispecific antibodies. The Company's main products include tetacept (RC18), veldicitumab (RC48) and dual-target fusion protein (RC28). The Company's products are mainly used to treat major diseases such as autoimmune diseases, oncology and ophthalmology. The Company mainly conducts its businesses in the domestic market.

  • Revenue in HKD (TTM)1.16bn
  • Net income in HKD-1.63bn
  • Incorporated2008
  • Employees3.62k
  • Location
    RemeGen Co LtdNo.1 Rongchang Road, Yantai ETDZYANTAI 264006ChinaCHN
  • Phone+86 5 353573511
  • Fax+86 5 356113517
  • Websitehttp://www.remegen.cn/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
SSY Group Ltd6.46bn1.32bn14.22bn5.60k10.822.058.132.200.44270.44272.172.330.56373.003.011,154,109.0011.5910.5115.5814.0356.0158.7220.5718.621.6029.610.31738.560.45059.1017.447.663.9413.56
Zai Lab Ltd2.27bn-2.65bn14.25bn2.18k--2.35--6.27-2.73-2.732.356.120.26972.845.61---31.41-37.72-36.81-42.7262.8664.75-116.45-282.444.43--0.0596--24.03360.0324.51---3.45--
Simcere Pharmaceutical Group Ltd7.13bn770.99m14.88bn7.03k19.711.9113.472.090.28920.28922.732.980.61063.532.651,014,326.006.6010.178.9415.6075.4378.8210.8017.501.870.97420.165246.684.497.92-23.22-0.521323.93--
3SBio Inc8.43bn1.67bn15.71bn5.41k9.561.027.581.860.67350.67353.456.310.34261.587.011,558,095.006.957.449.039.2984.9882.9120.3021.502.2622.720.2266--13.8411.26-19.133.948.78--
The United Laboratories Intl. Hldgs Ltd.14.82bn2.91bn16.77bn15.00k5.761.224.761.131.601.608.167.560.68713.366.15988,057.1013.517.8920.5212.6446.1144.1719.6612.731.74--0.105528.9921.2212.8470.8531.6624.1914.67
WuXi XDC Cayman Inc2.29bn305.85m17.44bn1.18k52.092.9647.187.610.27950.27952.134.91------1,944,763.00--------26.35--13.35--4.03--0.0005--114.44--82.07------
Grand Pharmaceutical Group Ltd10.53bn1.88bn17.68bn10.53k9.301.157.731.680.53560.53563.004.330.46922.9410.26999,581.408.4510.0911.6614.0161.9661.9718.0022.350.981922.960.183126.9410.1212.06-9.5921.415.6924.77
China Traditional Chinese Med Hldg CoLtd19.55bn1.39bn21.30bn17.30k15.370.93337.901.090.27530.27533.884.530.49851.472.161,129,723.003.844.605.857.0751.1857.077.709.771.489.830.177317.3526.699.9968.11-2.24-12.75--
RemeGen Co Ltd1.16bn-1.63bn21.82bn3.62k--3.67--18.80-3.03-3.032.156.890.18640.40054.31321,104.80-26.17-18.66-31.75-23.7576.4881.94-140.43-102.881.31-64.320.2682--40.16148.65-51.30--59.07--
Genscript Biotech Corp6.56bn-745.90m22.13bn6.94k--2.03--3.37-0.354-0.3543.115.120.2837.595.45945,459.50-11.97-18.34-18.27-26.1548.7854.68-42.30-64.914.65--0.1694--34.1729.4457.91--17.14--
HUTCHMED (China) Ltd6.55bn787.32m26.79bn1.99k34.264.6931.384.090.89760.89767.626.550.72587.197.693,293,109.008.76-14.3513.36-20.4354.1236.5712.06-31.442.60--0.1038--96.5231.38127.93--38.65--
Akeso Inc4.88bn2.19bn30.65bn2.78k13.555.8813.636.282.612.615.836.020.61680.374915.981,757,507.0026.47-11.5931.40-13.8796.96--42.91-42.494.3919.180.3983--440.35337.43273.60--63.99--
Data as of May 28 2024. Currency figures normalised to RemeGen Co Ltd's reporting currency: Hong Kong Dollar HKD

Institutional shareholders

26.40%Per cent of shares held by top holders
HolderShares% Held
E Fund Management Co., Ltd.as of 16 May 202415.03m7.93%
Zhong Ou Asset Management Co., Ltdas of 31 Dec 20237.24m3.82%
The Vanguard Group, Inc.as of 09 May 20245.52m2.91%
Harvest Fund Management Co., Ltd.as of 31 Dec 20234.96m2.62%
GF Fund Management Co., Ltd.as of 31 Dec 20233.75m1.98%
First Seafront Fund Management Co., Ltd.as of 31 Dec 20233.34m1.76%
Penghua Fund Management Co., Ltd.as of 31 Dec 20232.82m1.49%
Bosera Asset Management Co., Ltd.as of 31 Dec 20232.71m1.43%
Zheshang Fund Management Co., Ltd.as of 30 Jun 20232.43m1.28%
CITIC Securities Co., Ltd. (Invt Port)as of 31 Dec 20232.24m1.18%
More ▼
Data from 30 Jun 2023 - 22 May 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.